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a  b  s  t  r  a  c  t
The  efﬁcacy  of  sarolaner  (SimparicaTM, Zoetis)  was  evaluated  against  Demodex  spp.  in  dogs  with  gener-
alized  demodicosis  and  against  Otodectes  cynotis  (otodectic  mange)  in  dogs  with  induced  infestations.
In the  ﬁrst  study,  16  dogs  with  clinical  signs  of generalized  demodicosis  and  positive  for Demodex  spp.
mites  were  randomly  assigned  to treatment  with  either  sarolaner  (2 mg/kg)  orally  on Days  0,  30  and  60,
or topical  imidacloprid  (10  mg/kg)  plus  moxidectin  (2.5  mg/kg)  solution  every  7 days  from  Day 0  to  Day
81. For  sarolaner-treated  dogs,  pretreatment  mite  counts  were  reduced  by 97.1%  at 14  days  and  99.8% by
29  days  after  the  ﬁrst  dose,  with  no  live  mites  detected  thereafter.  Weekly  imidacloprid  plus  moxidectin
resulted  in 84.4  and  95.6%  reduction  at these  two time  points,  respectively,  with  no mites  detected  from
Day  74 on.  All  dogs  in  both  groups  showed  marked  improvement  in  the  clinical  signs  of  demodicosis.
In  the  second  study,  32  dogs  with  induced  infestations  of  O.  cynotis  were  randomly  assigned  (eight
per  group)  to oral  sarolaner  (2 mg/kg)  as  a single  treatment  on Day  0 or as  a two  dose  regime (Days  0
and  30),  or  a placebo  group  for  each  of the dose  regimes.  Sarolaner  administered  at  2  mg/kg  as  a single
oral  dose  resulted  in  a  98.2%  reduction  at Day  30  and  two doses  of sarolaner,  administered  one  month
apart,  resulted  in a 99.5%  reduction  in  ear  mites  at Day  60  compared  to  placebo  controls.  There  were  no
treatment  related  adverse  events  in  either  study.
In  these  studies,  sarolaner  at  an  oral  dose  of  2 mg/kg  was  highly  effective  in  reducing  the  live  mite
counts  associated  with  a natural  infestation  of  Demodex  spp.  and  an  induced  infestation  of O.  cynotis.  In
addition,  the Demodex-infested  dogs  showed  a marked  improvement  in the  clinical  signs  of  generalized
demodicosis.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Demodicosis is an inﬂammatory parasitic disease of dogs char-
cterized by the presence of larger than normal numbers of
emodex mites. Traditionally demodicosis was thought to be a dis-
ase caused by unchecked replication of Demodex canis mite though
ore recently Demodex injai and Demodex cornei (Forsythe et al.,
009; Sastre et al., 2012; Desch and Hillier, 2003) have also been
dentiﬁed in dogs with demodicosis. Demodex spp. mites are consid-
red a normal resident of the dog’s skin with transmission occurring
rom the dam to nursing neonates by direct contact during the ﬁrst
wo or three days of life. Four stages may  be demonstrated in skin
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/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
scrapings; eggs, larvae, nymphs and adults (Muller and Kirk, 2013).
Two types of demodicosis are recognized, localized and general-
ized, though there is no uniformly accepted standard as to how
many localized lesions are needed before the disease is character-
ized as generalized. Diagnosis is made based on clinical signs and
deep skin scrapings which conﬁrm the presence of the mites.
Generalized demodicosis is a severe condition that is difﬁcult to
control with currently approved therapies. Saturation applications
of amitraz solutions can be used for the treatment of generalized
demodicosis, although the application process is cumbersome as
it requires dipping or wetting the dog’s entire body and/or spong-
ing the product onto the dog for three to six treatments repeated
every 14 days. Higher doses may  increase efﬁcacy but tend to be
associated with increased adverse reactions (Mueller, 2004). Fre-
quently reported side effects include a temporary sedative effect
for 12–24 h, especially after the ﬁrst treatment, and some dogs
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ecome pruritic. A number of macrocyclic lactones used at off-label
osages and regimes have been shown to provide varying levels of
ffectiveness against Demodex spp. mites, though often the high
oses required can result in adverse reactions (Garﬁeld and Reedy,
992; Johnstone, 2002; Schnabl et al., 2010). High doses of oral
vermectin administered daily provided effective control of demod-
cosis over four month treatment intervals (Paterson et al., 2009,
014) but signs of toxicity are occasionally seen in dogs on thes high
ose regimes (Bissonnette et al., 2009). One macrocyclic lactone,
oxidectin, in combination with imidacloprid is effective for the
reatment of demodicosis when administered topically at monthly
r in severe cases at weekly intervals (Heine et al., 2005; Fourie
t al., 2009) and is approved with this indication in Europe. How-
ver, other clinical studies have reported lower efﬁcacy with this
roduct especially in dogs with moderate to severe clinical signs
f demodicosis (Mueller et al., 2009) and conﬁrmed that efﬁcacy
ncreased with frequency of application and treatment at weekly
ntervals was most effective (Paterson et al., 2009).
Otoacariasis or otodectic mange is caused by Otodectes cyno-
is,  an obligate parasite which inhabits the vertical and horizontal
ar canals of dogs and cats. Dogs infested with O. cynotis most
ommonly develop otitis externa characterized by vertical and hor-
zontal canal erythema and a dark brown, ceruminous otic exudate.
n addition to otitis externa, infestations of the head, neck, tail head
nd trunk can occur when the mites “escape” the ear canals. Pup-
ies appear to be most susceptible and zoonotic infections have
lso been reported (Curtis, 2004; Muller and Kirk, 2013). Diagnosis
f O. cynotis infestation is made by detection of mites within the
eruminous debris from an infected ear canal or by visualization of
ites on otoscopic examination.
A number of liquid aural preparations containing antifungals,
ntibiotics, steroids and/or parasiticides are licensed for the treat-
ent of O. cynotis infestations in dogs, but these have a limited
esidual action and require regular re-application for several days.
xtra-label aural administration of products containing pyrethrins
nd ivermectin (Muller and Kirk, 2013), and ﬁpronil (Bourdeau and
ecanu, 1999 Vincenti and Genchi, 1997) have also been reported
o be efﬁcacious on some occasions. Topical spot-on formulations
ncluding the macrocyclic lactones, selamectin and moxidectin,
dministered monthly are effective for the treatment and control
f O. cynotis infestations in dogs (Krieger et al., 2005; Six et al.,
000; Arther et al., 2015). Moxidectin administered orally, extra-
abel, at a dose of 0.2 mg/kg twice at 10 day intervals and has also
een shown to be effective (Muller and Kirk, 2013). Systemic prod-
cts with residual action offer an attractive therapeutic option for
eterinarians and owners.
Sarolaner (SimparicaTM, Zoetis) is a novel isoxazoline with
otent activity against ticks and ﬂeas (McTier et al., 2016), and
arcoptic mange mites (Becskei et al., 2016) following oral admin-
stration. Two exploratory studies were conducted in dogs to
valuate the efﬁcacy and safety of sarolaner against natural infesta-
ions of Demodex spp. and induced aural infestations of O. cynotis at
he minimum dose of 2 mg/kg proposed for monthly administration
or the treatment and control of ﬂeas and ticks.
. Materials and methods
Two laboratory studies were conducted in the Republic of South
frica in compliance with Good Clinical Practice (EMEA, 2000).
tudy protocols were reviewed and approved by ClinVet and Zoetis
nstitutional Animal Care and Use Committees. Masking of both
tudies was assured through the separation of functions. All per-
onnel conducting observations or animal care, or performing skin
crapings and or counts were masked to treatment allocation.tology 222 (2016) 62–66 63
2.1. Animals
In both studies, dogs were individually housed in enclosures that
allowed for auditory and visual contact without physical contact
and conformed to accepted animal welfare guidelines. Each dog
was individually identiﬁed by an alphanumeric microchip implant.
The dogs had not been treated with an ectoparasiticide for at least
90 days and were in good health at treatment. Dogs were fed an
appropriate maintenance ration of a commercial dry canine feed
for the duration of the study. Water was available ad lib.
The Demodex study included 16 (6 male and 10 female), locally
sourced, adult mongrel dogs ≥6 months of age and weighing from
6.2 to 23.1 kg. Dogs were enrolled in the study as suitable animals
with natural Demodex infestations were identiﬁed. Twelve dogs
were included in an initial enrolment and a further four dogs were
added approximately three months later. All enrolled dogs exhib-
ited clinical signs of generalized demodicosis; skin lesions such as
alopecia, erythema, comedones, papules, pustules, casts, scales or
crusts involving an entire body region or ﬁve or more localized
lesions containing areas (each with a diameter >2.5 cm), or podo-
demodicosis involving two  or more feet, and a total of at least four
live Demodex mites in deep skin scrapings (Muller and Kirk, 2013;
Mueller et al., 2012). In addition, they had not received a short act-
ing corticosteroid within one week or a long acting corticosteroid
within four weeks of Day 0.
Thirty-two (17 male and 15 female) adult, purpose bred Bea-
gles and mixed breed dogs, 1–7 years of age and weighing from
8.0 to 24.8 kg were used in the Otodectes study. O. cynotis infesta-
tions had been previously induced in these dogs by harvesting mites
by lavage from donor dogs with patent natural infestations and
transferring approximately 100 mites into each of the ears of the
recipient dogs. On Day −4, the presence of live mites was  conﬁrmed
by otoscopic examination.
2.2. Experimental design and methods
General methods: Day 0 was  deﬁned as the day an animal
received its ﬁrst treatment. Dogs were acclimated to the study
conditions for at least 14 days prior to treatment. A veterinarian
performed a physical examination on each dog to determine health
and suitability prior to inclusion in the study, and general health
observations were made at least once daily throughout the study.
Oral dosing was  conducted in the fed state. Food was  withheld the
evening prior to the morning of treatment, and dogs were offered
their standard ration one hour prior to dosing. Tablets were orally
administered by pilling to ensure accurate and complete dosing.
Each dog was observed for several minutes, and then at approx-
imately two  hours after dosing for evidence that the dose was
completely consumed. At 1, 3, 6 and 24 h post-dosing, all dogs
were observed for any signs of abnormal health. To avoid cross-
infestation or contamination of dogs during mite counts, study
personnel changed protective clothing between dogs in each treat-
ment group, utilized separate leashes, gloves and equipment with
each dog, and cleaned the surface of the examination Table used
for scraping and/or mite counting.
In the Demodex study, demodicosis was assessed by mite counts
and evaluation of clinical signs. Mite infestations were evaluated
using deep skin scrapings taken from ﬁve primary sites show-
ing the most severe clinical evidence of mite infestation based on
visual examination. The same ﬁve primary sites were scraped on
all days on which mites were counted. Scraped material was trans-
ferred to a slide, mixed with mineral oil and examined under a
microscope using 40× or 100× magniﬁcation to count adult and
immature mites. The clinical signs of demodicosis were assessed
as the percent of the body surface affected by skin lesions followed
by the assignment of a clinical score to each of four parameters: (1)
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Table  1
Geometric mean live Demodex mite counts, range, percent efﬁcacy relative to pretreatment and the proportion of dogs with no live mites for dogs treated with three monthly
oral  doses of sarolaner or receiving weekly topical applications of imidacloprid plus moxidectin.
Study day
−4 14 29 44 59 74 91
Sarolaner (n = 8) Mean count 260.5 7.5*,** 0.4*,** 0.0* 0.0* 0.0* 0.0*
Range 4–1275 0–315 0–8 0–0 0–0 0–0 0–0
Efﬁcacy (%) – 97.1 99.8 100 100 100 100
Mite  free (%) 0 37.5 75 100 100 100 100
Imidacloprid plus
moxidectin (n = 8)
Mean count 243.2 37.8* 10.8* 0.7* 0.1* 0.0* 0.0*
Range 17–2820 0–1733 0–383 0–9 0–1 0–0 0–0
Efﬁcacy (%) – 84.4 95.6 99.7 >99.9 100 100





































m* Post-treatment geometric mean live mite counts signiﬁcantly lower than pre-tr
*,** Geometric mean live mite counts for sarolaner signiﬁcantly lower than imidacl
omedones, pustules and papules, (2) casts, crusts and scales, (3)
lopecia and (4) erythema. Following the Day −4 assessments, dogs
ere ranked in blocks of two by descending mite count and ran-
omly allocated to treatment with either sarolaner (SimparicaTM,
oetis) or the positive control, topical imidacloprid plus moxidectin
Advocate®/Advantage® Multi Spot-on solution for Dogs, 100 mg
midacloprid + 25 mg  moxidectin/mL, Bayer). Dogs in the sarolaner
roup were dosed orally with a single tablet that was shaved or
anded to provide the target dose of 2 mg/kg of sarolaner on Days 0,
0 and 60. Positive control dogs were dosed topically once weekly
rom Day 0 to Day 81 with the appropriate band dose providing
10 mg  imidacloprid + ≥2.5 mg  moxidectin/kg, per European label
irections for dogs with severe generalized demodicosis. Doses
ere calculated based on the most recent body weights determined
n Days −3, 29 and 59. All dogs were examined for the clinical signs
f demodicosis and skin scrapings/mite counts were performed on
ays 14, 29, 44, 59, 74 and 91.
In the Otodectes study, dogs were weighed and examined oto-
copically on Day −4, and 32 animals positive for live mites were
elected for inclusion in the study. Sixteen animals were allocated
o a single treatment on Day 0, the other 16 to a two  dose treat-
ent regime (Days 0 and 30). Within each dosing regimen, dogs
ere assigned to treatment with either placebo or sarolaner oral
ablet (eight per group) and to individual pens using a randomized
omplete block design. Dogs in the sarolaner-treated groups were
osed orally with single tablets shaved and/or sanded to provide the
arget dose of 2 mg/kg. Control dogs received single placebo tablets.
ay 0 dose was calculated using the Day −4 body weight and dogs
eceiving two doses were also weighed on Day 28 for calculation
f the Day 30 dose. Dogs in the single dose groups were examined
toscopically for the presence of live mites on Day 14 and total ear
ite counts conducted on Day 30. Dogs in the two-dose groups
ere examined with an otoscope on Days 14 and 44, and had total
able 2
valuation of the clinical signs of demodicosis for dogs treated with three monthly ora
oxidectin; mean percent body area affected by lesions and the proportions of dogs with
Study day
−4 
Sarolaner (n = 8) Body area affected (%) 69 
Casts, scales, crusts 100 




moxidectin (n = 7)a
Body area affected (%) 66 
Casts, scales, crusts 100 
Comedones, papules, pustules 14.3 
Alopecia 100 
Erythema 61.4 
a One dog was excluded from assessment of clinical signs due to concurrent antibiotic ent (P < 0.0001).
plus moxidectin (P < 0.0331).
mite counts performed on Day 60. For total mite counts, dogs were
sedated and each ear was  ﬂushed and processed separately. The ear
canals were ﬁlled with Docusol® (5% docusate sodium) and mas-
saged to loosen the contents. The docusate sodium solution was
then removed from the ears and poured through a 38 m sieve.
The ears were then ﬂushed with a warm saline solution which was
poured through the same sieve. The ears were examined otoscopi-
cally and if needed the ﬂushing process was repeated until the ear
canals were assessed as clean (no visible cerumen or mites). The
contents of the sieve were rinsed with water and transferred to a
Petri dish for examination under a stereo microscope. All live mites
(adults, larvae and nymphs) were counted and the counts for the
two ears were summed for each animal’s total mite count.
2.3. Data analysis
All calculations were performed using SAS version 9.2 (SAS Insti-
tute, Cary, NC, USA). The individual dog was the experimental unit.
Mite counts were transformed by the loge(count + 1) transforma-
tion prior to analysis in order to stabilize the variance and normalize
the data. Differences were assessed at the two-sided signiﬁcance
level  = 0.05. Geometric means (back transformed means) were
calculated from the least squares means. Efﬁcacy (% reduction) was
calculated versus the pretreatment count or placebo using the fol-
lowing formula:
%Efficacy
= (Mean Pretreatment[Placebo]Count - Mean Post-treatment Count)
Mean Pretreatment[Placebo]Count
× 100Live Demodex mite counts were analyzed using a mixed linear
model for repeated measures; including the ﬁxed effect of treat-
ment, day of study and interaction between treatment and day of
l doses of sarolaner or receiving weekly topical applications of imidacloprid plus
 the different lesion types present.
14 29 44 59 74 91
60 26 7 4 2 1
100 87.5 75.0 37.5 25.0 12.5
25.0 0.0 0.0 0.0 0.0 0.0
100 100 87.5 50.0 12.5 12.5
25.0 37.5 12.5 25.0 37.5 12.5
51 16 8 6 3 2
85.7 42.9 28.6 42.9 28.6 14.3
14.3 0.0 0.0 0.0 0.0 0.0
100 71.4 57.1 42.9 28.6 28.6
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tudy. The random effects included batch, block within batch, the
nteraction between block and treatment within batch and error. In
ddition for each clinical assessment, the frequency of dogs in each
roup with no live mites, the frequency distribution of skin lesion
everity for each lesion type, and percent change from baseline of
he extent of skin lesions were determined.
Total live Otodectes mite counts at Day 30 and 60 were analyzed
sing a mixed linear model including the ﬁxed effect of treatment
nd random effects of block and error.
. Results
.1. Efﬁcacy
Prior to treatment initiation, all dogs included in the Demodex
tudy had infestations of mites with geometric mean counts of
pproximately 250 live mites/dog in each group. Both treatments
esulted in a rapid reduction in the numbers of live mites (Table 1)
ith all post treatment counts (from Day 14 on) signiﬁcantly
ower than the pretreatment counts (P ≤ 0.0001). This reduction
as notably more rapid for the oral sarolaner treatment with mite
ounts for this treatment being signiﬁcantly lower than those for
he imidacloprid plus moxidectin group on Day 14 (P = 0.0331) and
ay 29 (P = 0.0038). Mean counts were not signiﬁcantly different on
ubsequent examinations (P > 0.05). The proportions of dogs that
ere free of live mites in the sarolaner-treated group were 37.5%
n Day 14, 75% on Day 29, and 100% on all subsequent days. For
ogs receiving weekly topical imidacloprid plus moxidectin, 37.5%
ere free of live mites on Days 14 and 29, 62.5% on Day 44, 87.5% on
ay 59 and all dogs had no live mites detected thereafter (Table 1).
In this study, one imidacloprid plus moxidectin-treated dog
as excluded from the assessment of clinical sign progression due
o concurrent treatment for an accidental laceration with a sys-
emic antibiotic and non-steroidal anti-inﬂammatory that could
ave aided in the resolution of clinical signs of demodicosis. Begin-
ing on Day 14, there was improvement noted in the clinical signs
f demodicosis in both treatment groups that continued through all
ubsequent time points (Table 2). Comedones, papules and pustules
ad resolved completely by Day 29 in both treatment groups. By
he end of the study, casts, crusts and scales had resolved in all but
ne dog in each treatment group, while alopecia and erythema had
esolved in all but one sarolaner-treated dog and two dogs in the
midacloprid plus moxidectin-treated group. Similarly, the aver-
ge proportion of body surface affected by skin lesions relating to
emodicosis was markedly reduced from about 65% pretreatment
o 1–2% by the end of the study.
In the Otodectes study, qualitative otoscopic exams on Day 14
emonstrated live mites in six of eight placebo-treated dogs, and
hree of eight sarolaner-treated dogs in the single dose regimen.
t 30 days after a single oral treatment, live mites were recov-
red from seven of eight placebo-treated dogs and only two  of
he eight sarolaner-treated dogs. The respective geometric mean
ite counts were 35.1 and 0.6, resulting in 98.2% efﬁcacy (Table 3).
he mean count for the sarolaner-treated group was  signiﬁcantly
ower than that for placebo-treated group (P = 0.0013). In the two
ose regimen, qualitative otoscopic exams on Day 14 demon-
trated live mites in four of eight placebo-treated dogs and ﬁve
f eight sarolaner-treated dogs, and on Day 44 (14 days after the
econd treatment), revealed live mites in four of eight placebo
ogs and none of the sarolaner-treated dogs. At 30 days after two
onthly oral treatments, live mites were recovered from ﬁve of
ight placebo-treated dogs and only a single live mite was found in
ne of the eight sarolaner-treated dogs. The respective geometric
ean counts were 19.1 and 0.1, resulting in 99.5% efﬁcacy (Table 3).tology 222 (2016) 62–66 65
The mean count for the sarolaner-treated group was  signiﬁcantly
lower than for the placebo-treated group (P = 0.0195).
3.2. Treatment
In both studies, all dogs treated with oral tablets were dosed
completely; no tablets were expelled and no evidence of eme-
sis was  observed in any animal. In the Demodex study, all dogs
treated with the imidacloprid plus moxidectin solution received
the appropriate topical dose, however a negligible amount of runoff
was noted on a few occasions. This is not unexpected following
application of a topical liquid formulation.
3.3. Health observations
There were no adverse events in any either study that were
considered related to treatment with sarolaner.
4. Discussion
The two  studies reported here conﬁrmed the systemic acarici-
dal efﬁcacy of the novel isoxazoline, sarolaner, against two  mite
species commonly infesting dogs. A single oral dose at 2.0 mg/kg
resulted in >97% reduction in Demodex mite counts at 14 days
and >99% at 29 days with a corresponding improvement in the
clinical signs of demodicosis. Following a second monthly treat-
ment, no live mites were recovered from any sarolaner-treated dog.
This level of efﬁcacy compared favorably to that of the commer-
cial comparator (topical imidacloprid plus moxidectin) applied at
the recommended dosage and greatest frequency, as a dog in that
group continued to harbor live mites until Day 59, at which time
11 weekly treatments had been administered.
For dogs with induced aural infestations of O. cynotis, sarolaner
administered at 2 mg/kg as a single oral dose resulted in a 98.2%
reduction and two  doses of sarolaner, administered one month
apart, resulted in a 99.5% reduction in ear mites compared to
placebo-treated controls.
Generalized demodectic mange is a serious, debilitating and
often life-threatening disease that may  be difﬁcult to treat; avail-
able therapies generally require repeated application over lengthy
periods and often at off-label dosages. Side effects are not uncom-
mon  at effective dose rates and dogs need to be monitored closely
(Johnstone, 2002; Bissonnette et al., 2009). This study was  con-
ducted with a positive control and no negative control group due to
welfare concerns. Thus, the possibility of self-cure in these animals
cannot be discounted and effectiveness of treatments may  be over-
estimated in the model and not truly reﬂect the effectiveness seen
in a clinical situation. That said, all dogs included in the study had
clinical signs of generalized demodecosis which as a chronic disease
is considered unlikely to resolve without treatment (Paradis and
Page, 1998). In this study, sarolaner was  administered at the mini-
mum  dose recommended for month-long control of ﬂeas and ticks
and provided effective control of Demodex mites (99.8%) follow-
ing a single dose, with apparent eradication of mites following the
second monthly dose with concurrent rapid resolution of clinical
signs indicating the potential of sarolaner for convenient treatment
of generalized demodicosis. Notably, sarolaner was as, if not more,
effective than intensive (weekly) treatment with an approved top-
ical product. The efﬁcacy seen with sarolaner was also comparable
to that of off-label, oral ivermectin treatment which has been
shown to be more effective than topical moxidectin plus imidaclo-
prid (Paterson et al., 2009, 2014). This potent systemic, miticidal
efﬁcacy of the isoxazoline class has also been demonstrated for
another compound, ﬂuralaner, which demonstrated similar efﬁ-
cacy after oral administration in dogs with generalized demodicosis
(Fourie et al., 2015).
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Table  3
Geometric mean total ear mite counts, range and percent efﬁcacy relative to placebo for dogs with induced infestations of Otodectes cynotis and treated with either a single
oral  dose or two monthly doses of a sarolaner.
n Count Day Live mite count
Treated Treatment Mean Range Efﬁcacy (%)
Day 0 Placebo 8 30 35.1 0–636 –
Sarolaner 8 30 0.6* 0–11 98.2




































selamectin against Sarcoptes scabei on dogs and Otodectes cynotis on dogs and
cats presented as veterinary patients. Vet. Parasitol. 91, 291–309.
®Sarolaner 8 
* Geometric mean live mite count for sarolaner signiﬁcantly lower than placebo 
** Geometric mean live mite count for sarolaner signiﬁcantly lower than placebo 
Ear mites are also ubiquitous parasites of dogs and sarolaner
dministered orally at 2 mg/kg was highly effective against induced
nfestation after a single dose or two monthly doses. This level of
fﬁcacy was as good, or better, than that expected for topically
dministered products for the treatment of ear mite infestations.
There were no adverse reactions to treatment with oral
arolaner in these studies. This, combined with the excellent efﬁ-
acy against both Demodex spp. and O. cynotis mites following one
o two monthly treatments, indicates the potential of sarolaner for
he convenient and effective treatment of these mite infestations
nd their associated diseases in dogs.
. Conclusions
Monthly oral administration of sarolaner at 2 mg/kg to dogs
ith generalized demodicosis was highly effective in eliminating
ites and resolving clinical signs of the disease. Pretreatment mite
ounts were reduced by 97.1% at 14 days and 99.8% at 29 days
fter the ﬁrst dose, with no live mites detected thereafter. All dogs
howed marked improvement in the clinical signs of demodicosis.
gainst an induced infestation of O. cynotis in dogs, this dose of oral
arolaner reduced mite counts by 98.2% after a single dose and by
9.5% after two monthly doses.
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